Uploaded June 2026 | Updated September 2026, 1 week ago

---

Johnson & Johnson has no plans to enter the booming obesity market, opting instead to focus on diseases such as cancer, CEO Joaquin Duato said in an interview for an upcoming episode of The David Rubenstein Show: Peer to Peer Conversations. The comments set J&J apart from many of its rivals that are trying to develop or acquire obesity medicines following blockbuster weight-loss drugs from Eli Lilly & Co. and Novo Nordisk.
--------
Like this video? Subscribe to The David Rubenstein Show on YouTube:
youtube.com/channel/UCqsN9MYiu1mKSAsYoF6ppTg

Watch the latest episodes of "The David Rubenstein Show: Peer-to-Peer Conversations" here:
bloomberg.com/peer-to-peer

Learn more about David:
davidrubenstein.com
Connect with us on...
Twitter: twitter.com/business
Facebook: facebook.com/bloombergbusiness
Instagram: instagram.com/bloombergbusiness